{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T11:11:26Z","timestamp":1762341086129,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10549-018-4684-3","type":"journal-article","created":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:30:50Z","timestamp":1517445050000},"page":"391-396","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience"],"prefix":"10.1007","volume":"169","author":[{"given":"Nicholas B.","family":"Figura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sepideh","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold B.","family":"Etame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nam D.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather S.","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solmaz","family":"Sahebjam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Forsyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3331-1529","authenticated-orcid":false,"given":"Kamran A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,1]]},"reference":[{"key":"4684_CR1","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719\u2013726. \n                    https:\/\/doi.org\/10.1200\/JCO.2002.20.3.719","journal-title":"J Clin Oncol"},{"key":"4684_CR2","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1002\/cncr.11436","volume":"97","author":"JC Bendell","year":"2003","unstructured":"Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, Bunnell C, Rue M, Gelman R, Winer E (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972\u20132977. \n                    https:\/\/doi.org\/10.1002\/cncr.11436","journal-title":"Cancer"},{"key":"4684_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13058-015-0665-1","volume":"18","author":"I Witzel","year":"2016","unstructured":"Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H (2016) Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res 18:8. \n                    https:\/\/doi.org\/10.1186\/s13058-015-0665-1","journal-title":"Breast Cancer Res"},{"key":"4684_CR4","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.18632\/oncotarget.5911","volume":"7","author":"BJ Scott","year":"2016","unstructured":"Scott BJ, Oberheim-Bush NA, Kesari S (2016) Leptomeningeal metastasis in breast cancer\u2014a systematic review. Oncotarget 7:3740\u20133747. \n                    https:\/\/doi.org\/10.18632\/oncotarget.5911","journal-title":"Oncotarget"},{"key":"4684_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11060-013-1092-8","volume":"113","author":"E Rhun Le","year":"2013","unstructured":"Le Rhun E, Taillibert S, Zairi F, Kotecki N, Devos P, Mailliez A, Servent V, Vanlemmens L, Vennin P, Boulanger T, Baranzelli MC, Andre C, Marliot G, Cazin JL, Dubois F, Assaker R, Bonneterre J, Chamberlain MC (2013) A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer. J Neurooncol 113:83\u201392. \n                    https:\/\/doi.org\/10.1007\/s11060-013-1092-8","journal-title":"J Neurooncol"},{"key":"4684_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1186\/s12885-015-2042-y","volume":"15","author":"G Mittica","year":"2015","unstructured":"Mittica G, Senetta R, Richiardi L, Ruda R, Coda R, Castellano I, Sapino A, Cassoni P (2015) Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients. BMC Cancer 15:1021. \n                    https:\/\/doi.org\/10.1186\/s12885-015-2042-y","journal-title":"BMC Cancer"},{"key":"4684_CR7","doi-asserted-by":"publisher","first-page":"e151","DOI":"10.1200\/JCO.2012.44.8894","volume":"34","author":"G Bousquet","year":"2016","unstructured":"Bousquet G, Darrouzain F, de Bazelaire C, Ternant D, Barranger E, Winterman S, Madelaine-Chambin I, Thiebaut JB, Polivka M, Paintaud G, Culine S, Janin A (2016) Intrathecal trastuzumab halts progression of CNS metastases in breast cancer. J Clin Oncol 34:e151\u2013e155. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.44.8894","journal-title":"J Clin Oncol"},{"key":"4684_CR8","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40425-015-0084-y","volume":"3","author":"NT Lu","year":"2015","unstructured":"Lu NT, Raizer J, Gabor EP, Liu NM, Vu JQ, Slamon DJ, Barstis JL (2015) Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient. J Immunother Cancer 3:41. \n                    https:\/\/doi.org\/10.1186\/s40425-015-0084-y","journal-title":"J Immunother Cancer"},{"key":"4684_CR9","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/annonc\/mdn654","volume":"19","author":"O Mir","year":"2008","unstructured":"Mir O, Ropert S, Alexandre J, Lemare F, Goldwasser F (2008) High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann Oncol 19:1978\u20131980. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdn654","journal-title":"Ann Oncol"},{"key":"4684_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.4143\/crt.2014.234","volume":"48","author":"WY Park","year":"2016","unstructured":"Park WY, Kim HJ, Kim K, Bae SB, Lee N, Lee KT, Won JH, Park HS, Lee SC (2016) Intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis. Cancer Res Treat 48:843\u2013847. \n                    https:\/\/doi.org\/10.4143\/crt.2014.234","journal-title":"Cancer Res Treat"},{"key":"4684_CR11","first-page":"1373","volume":"15","author":"HJ Stemmler","year":"2006","unstructured":"Stemmler HJ, Schmitt M, Harbeck N, Willems A, Bernhard H, Lassig D, Schoenberg S, Heinemann V (2006) Application of intrathecal trastuzumab (herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 15:1373\u20131377","journal-title":"Oncol Rep"},{"key":"4684_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-013-2525-y","volume":"139","author":"F Zagouri","year":"2013","unstructured":"Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, Dimopoulos MA, Preusser M (2013) Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res Treat 139:13\u201322. \n                    https:\/\/doi.org\/10.1007\/s10549-013-2525-y","journal-title":"Breast Cancer Res Treat"},{"key":"4684_CR13","first-page":"117","volume":"3","author":"BJ Scott","year":"2013","unstructured":"Scott BJ, Kesari S (2013) Leptomeningeal metastases in breast cancer. Am J Cancer Res 3:117\u2013126","journal-title":"Am J Cancer Res"},{"key":"4684_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/01.cad.0000236313.50833.ee","volume":"18","author":"HJ Stemmler","year":"2007","unstructured":"Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V (2007) Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 18:23\u201328. \n                    https:\/\/doi.org\/10.1097\/01.cad.0000236313.50833.ee","journal-title":"Anticancer Drugs"},{"key":"4684_CR15","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1200\/JCO.2005.07.144","volume":"23","author":"Y Cao","year":"2005","unstructured":"Cao Y, Tsien CI, Shen Z, Tatro DS, Ten Haken R, Kessler ML, Chenevert TL, Lawrence TS (2005) Use of magnetic resonance imaging to assess blood-brain\/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 23:4127\u20134136. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.07.144","journal-title":"J Clin Oncol"},{"key":"4684_CR16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.breast.2011.05.007","volume":"20","author":"M Mego","year":"2011","unstructured":"Mego M, Sycova-Mila Z, Obertova J, Rajec J, Liskova S, Palacka P, Porsok S, Mardiak J (2011) Intrathecal administration of trastuzumab with cytarabine and methotrexate in breast cancer patients with leptomeningeal carcinomatosis. Breast 20:478\u2013480. \n                    https:\/\/doi.org\/10.1016\/j.breast.2011.05.007","journal-title":"Breast"},{"key":"4684_CR17","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/CAD.0b013e32830b58b0","volume":"19","author":"HJ Stemmler","year":"2008","unstructured":"Stemmler HJ, Mengele K, Schmitt M, Harbeck N, Laessig D, Herrmann KA, Schaffer P, Heinemann V (2008) Intrathecal trastuzumab (herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report. Anticancer Drugs 19:832\u2013836. \n                    https:\/\/doi.org\/10.1097\/CAD.0b013e32830b58b0","journal-title":"Anticancer Drugs"},{"key":"4684_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/neuonc\/now197","volume":"19","author":"M Chamberlain","year":"2017","unstructured":"Chamberlain M, Junck L, Brandsma D, Soffietti R, Ruda R, Raizer J, Boogerd W, Taillibert S, Groves MD, Le Rhun E, Walker J, van den Bent M, Wen PY, Jaeckle KA (2017) Leptomeningeal metastases: a RANO proposal for response criteria. Neuro-Oncology 19:484\u2013492. \n                    https:\/\/doi.org\/10.1093\/neuonc\/now183","journal-title":"Neuro-Oncology"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-018-4684-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4684-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-018-4684-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T22:13:49Z","timestamp":1548972829000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-018-4684-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,1]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["4684"],"URL":"https:\/\/doi.org\/10.1007\/s10549-018-4684-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2018,2,1]]},"assertion":[{"value":"13 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}